SCHEMBL1045503

SCHEMBL1045503

[O]c1cc(Cl)ccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318986 0.77
SCHEMBL15352416 0.74
SCHEMBL3982818 0.72
SCHEMBL8074926 0.72
SCHEMBL1806191 0.72
SCHEMBL8873179 0.71 TP53 (1.00)
SCHEMBL29349499 0.71
SCHEMBL22730 0.71
SCHEMBL167920 0.71
Formaldehyde SCHEMBL28747804 0.71 TP53 (0.82)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114409611-A Oxadiazole hydrazide compound and preparation method and application thereof 贵州大学 2022-04-29 CN claimed
EP-2396316-B1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-07-01 EP claimed
US-8937078-B2 Quinazolinones as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-01-20 US claimed
CN-102388037-B Quinazolinones as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV 2014-12-03 CN claimed
EP-2396316-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2011-12-21 EP claimed
WO-2010093727-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-19 WO claimed
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-12 US claimed
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-04-23 US claimed
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-12-06 US claimed
EP-1718653-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY Ligand Pharmaceuticals Inc. (US) 2006-11-08 EP claimed
EP-1607396-A1 Bicyclic inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2005-12-21 EP claimed
WO-2005082909-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY LIGAND PHARMACEUTICALS INCORPORATED (US) 2005-09-09 WO claimed
EP-1240168-B1 BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORP (US) 2005-08-31 EP claimed
US-6800632-B2 FOR TREATMENT OF DISORDERS MEDIATED BY GSK3 ACTIVITY, SUCH AS DIABETES, ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS, OBESITY, ATHEROSCLEROTIC CARDIOVASCULAR DISEASE CHIRON CORPORATION 2004-10-05 US claimed
US-20030008866-A1 Bicyclic inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2003-01-09 US claimed
EP-1240168-A1 BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 2002-09-18 EP claimed
US-20010044436-A1 Bicyclic inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2001-11-22 US claimed
WO-2001044246-A1 BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 2001-06-21 WO claimed
US-20230278994-A1 HETEROCYCLYL PYRIMIDINES AND TRIAZINES AS NOVEL FUNGICIDES BAYER AKTIENGESELLSCHAFT (DE) 2023-09-07 US disclosed
US-3996191-A DIOXAZINE DYES CIBA-GEIGY AG (CH) 1976-12-07 US disclosed